Ascendis Pharma (ASND) announced that the U.S. Food & Drug Administration, FDA, has approved SKYTROFA for the replacement of endogenous growth hormone in adults with growth hormone deficiency, a rare disorder resulting from decreased or total loss of growth hormone production. Lonapegsomatropin is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. The FDA’s approval of SKYTROFA for adult GHD was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled and active-controlled clinical trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily somatropin in adults with GHD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma’s Strong Market Performance and Potential Drive Buy Recommendation
- Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
- Ascendis Pharma’s Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating
- Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
- Ascendis Pharma’s Cancer Study Termination: Implications for Investors